Clinical efficacy and safety of nebulized prostacyclin in patients with sARs-CoV-2 (prospective comparative study) [клиНичеСкая ЭффективНоСть и безоПаСНоСть ПримеНеНия иНГаляциоННоГо ПроСтациклиНа у больНых С иНфекцией, вызваННой SARS-COV-2 (ПроСПективНое СравНительНое иССледоваНие)]

K. Zhdanov; K. Kozlov; K. Kas’janenko; S. Zakharenko; V. Sukachev; N. L’vov; O. Mal’tsev; D. Lavrenchuk; I. Lapikov; V. Sharabhanov; R. Mukhtarov; M. Bulygin; V. Potapenko; E. Malikova; M. Nepomnjashchikh; B. Mursalov; A. Sheraliev; M. Pervakova; S. Lapin

Статья

Clinical efficacy and safety of nebulized prostacyclin in patients with sARs-CoV-2 (prospective comparative study) [клиНичеСкая ЭффективНоСть и безоПаСНоСть ПримеНеНия иНГаляциоННоГо ПроСтациклиНа у больНых С иНфекцией, вызваННой SARS-COV-2 (ПроСПективНое СравНительНое иССледоваНие)]

K. Zhdanov, K. Kozlov, K. Kas’janenko, S. Zakharenko, V. Sukachev, N. L’vov, O. Mal’tsev, D. Lavrenchuk, I. Lapikov, V. Sharabhanov, R. Mukhtarov, M. Bulygin, V. Potapenko, E. Malikova, M. Nepomnjashchikh, B. Mursalov, A. Sheraliev, M. Pervakova, S. Lapin,

2021

https://doi.org/10.22625/2072-6732-2020-12-3-34-41

Aim. In this study we evaluated clinical effectiveness and safety of nebulized prostacyclin in patients with Novel Coronavirus Disease (SARS-CoV-2). Materials and methods: We have included 44 male patients with moderate PCR confirmed SARS-CoV-2 infection in this study. Control group consisted of 23 patients treated with nebulized prostacyclin (PGI2). besides standard therapy. We compared intensiveness and duration of infectious intoxication syndrome, duration of fever, cough as well as SpO2 level, complete blood count and chemokine status values. Results: Statistically significant difference in duration of fever, cough, intensiveness and duration of infectious intoxication syndrome were observed. Lymphocyte and platelet counts were significantly higher in control group We have also noticed significantly lower level of proinflammatory mediators and C4-complement component in control group. Only 1 adverse effect associated with inhaled prostacyclin was reported. Conclusion. Nebulized prostacyclin showed therapeutic efficacy and good safety profile in adults with moderate CO-VID-19. © 2020 Interregional public organization Association of infectious disease specialists of Saint-Petersburg and Leningrad region (IPO AIDSSPbR). All rights reserved.

Цитирование

Документы

Источник

Версии

1. Version of Record от 2021-04-27

Метаданные

Об авторах

K. Zhdanov
Military Medical Academy named after S.M. Kirov, Saint-Petersburg, Russian Federation
K. Kozlov
Promotion of Safe Information Technologies Development Foundtion, Moscow, Russian Federation
K. Kas’janenko
City Clinical hospital № 31, Saint-Petersburg, Russian Federation
S. Zakharenko
Russian Research Center for Radiology and Surgical Technologies named after academicican A.M. Granov, Saint-Petersburg, Russian Federation
V. Sukachev
First Saint-Petersburg State Medical University named after academician I.P. Pavlov, Saint-Petersburg, Russian Federation
N. L’vov
O. Mal’tsev
D. Lavrenchuk
I. Lapikov
V. Sharabhanov
R. Mukhtarov
M. Bulygin
V. Potapenko
E. Malikova
M. Nepomnjashchikh
B. Mursalov
A. Sheraliev
M. Pervakova
S. Lapin

Название журнала

Jurnal Infektologii

Том

Выпуск

Страницы

34-41

Ключевые слова

chemokine; complement component C4; prostacyclin; Article; blood cell count; clinical article; controlled study; coronavirus disease 2019; coughing; disease duration; drug efficacy; drug safety; fever; human; lymphocyte count; male; mediator; nebulization; platelet count; polymerase chain reaction; unspecified side effect

Издатель

Interregional public organization Association of infectious disease specialists of Saint-Petersburg and Leningrad region (IPO AIDSSPbR)

Тип документа

journal article

Тип лицензии Creative Commons

Правовой статус документа

Свободная лицензия

Источник

scopus

Поиск по репозиторию

Статья

Похожие публикации

Документы

Источник

Версии

Метаданные